<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20260212</date><key>collection.key</key><document><id>PMC12887308</id><infon key="license">CC BY-NC-ND</infon><passage><infon key="article-id_doi">10.21037/tgh-25-99</infon><infon key="article-id_pmc">PMC12887308</infon><infon key="article-id_publisher-id">tgh-11-25-99</infon><infon key="elocation-id">25</infon><infon key="kwd">Inflammatory bowel disease (IBD) hepcidin anemia of inflammation iron systematic review</infon><infon key="license">Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.</infon><infon key="name_0">surname:Parreira;given-names:Livia Fontana</infon><infon key="name_1">surname:Teixeira;given-names:Adherbal Víctor Rodrigues</infon><infon key="name_2">surname:Siqueira;given-names:Sofia Souza Nunes</infon><infon key="name_3">surname:Siqueira;given-names:Natalia Souza Nunes</infon><infon key="name_4">surname:de Castro;given-names:Marina Moreira</infon><infon key="name_5">surname:Genaro;given-names:Lívia Moreira</infon><infon key="name_6">surname:Pereira;given-names:Isabela Machado</infon><infon key="name_7">surname:Gallina;given-names:Nicole Compagnoni</infon><infon key="name_8">surname:Leal;given-names:Raquel Franco</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords: </infon><infon key="type">front</infon><infon key="volume">11</infon><infon key="year">2026</infon><offset>0</offset><text>The role of hepcidin in the inflammatory and iron homeostasis axis in inflammatory bowel diseases: a systematic review</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>119</offset><text>Background</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>130</offset><text>Inflammatory bowel disease (IBD), which encompasses Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation of the gastrointestinal tract. Anemia is a common complication in patients with IBD, significantly impacting quality of life. Hepcidin, the primary regulator of iron metabolism, exhibits increased expression during inflammatory states, contributing to the development of anemia of inflammation. Understanding the relationship between hepcidin and IBD is essential to improving the diagnosis and management of this complication. This article aimed to systematically review and synthesize the evidence on the associative and predictive utility of hepcidin as a biomarker for inflammatory activity, iron status, and anemia management in patients with IBD.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>928</offset><text>Methods</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>936</offset><text>A systematic review (SR) (PROSPERO identification number: CRD42024375586) was conducted across the databases PubMed, PubMed PMC, BVS/BIREME, Scopus, Web of Science, Embase, EBSCOhost, and ProQuest, including studies published up to July 2024. The research question was structured using the PICO strategy (Patient/Problem, Intervention, Comparison, and Outcome) to guide study selection and analysis. Original articles investigating hepcidin expression in patients with IBD and its association with inflammatory markers and iron status were included. Study selection, data extraction, and methodological quality assessment were performed independently by three reviewers using the Rayyan platform.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>1633</offset><text>Results</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>1641</offset><text>Of the 342 studies identified, 47 met the inclusion criteria for qualitative analysis. The majority of studies reported elevated hepcidin levels in patients with active IBD compared to healthy controls or patients in remission. Hepcidin expression was positively correlated with inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), and negatively correlated with serum iron parameters and hemoglobin levels.</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract_title_1</infon><offset>2076</offset><text>Conclusions</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>2088</offset><text>Hepcidin plays a central role in the pathophysiology of anemia associated with IBD, reflecting systemic inflammatory status. Its quantification may represent a valuable tool for the differential diagnosis of anemia and for guiding targeted therapies. Further longitudinal studies are required to validate its routine clinical use.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_caption</infon><offset>2419</offset><text>Highlight box</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>2433</offset><text>Key findings</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>2446</offset><text>• Hepcidin is a central regulatory peptide of iron metabolism and an emerging inflammatory marker in inflammatory bowel disease (IBD), being associated with anemia of inflammation. Patients with IBD, especially during active disease phases, present elevated hepcidin levels, which contribute to reduced iron absorption and mobilization. This systematic review analyzed studies correlating serum hepcidin levels with inflammatory activity, types of IBD (Crohn’s disease and ulcerative colitis), and the presence of anemia.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>2972</offset><text>What is known, and what is new?</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>3004</offset><text>• Hepcidin is regulated by inflammatory cytokines, especially interleukin-6, and its levels increase in chronic inflammation such as IBD. Anemia is a common manifestation in IBD, often multifactorial, including iron deficiency and inflammation.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>3251</offset><text>• This systematic review gathered evidence on the utility of hepcidin as a biomarker to distinguish iron-deficiency anemia from anemia of inflammation in IBD. Variations in hepcidin assay methods and study populations were identified, which affected the standardization of results. Most studies found a correlation between elevated hepcidin and disease activity, particularly in Crohn’s disease. Some studies suggest hepcidin may predict the response to intravenous versus oral iron therapy.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>3747</offset><text>What is the implication, and what should change now?</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>3800</offset><text>• Measuring hepcidin levels may enhance the diagnostic evaluation of anemia in IBD, enabling more targeted and effective therapies. Standardizing assay methods and defining reference ranges are essential steps for making hepcidin a reliable clinical biomarker. Hepcidin has the potential to be included in the panel for assessing inflammatory activity in IBD patients, especially when combined with other markers such as C-reactive protein and ferritin.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>4256</offset><text>Introduction</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4269</offset><text>Inflammatory bowel disease (IBD) is a term that primarily encompasses two chronic conditions: Crohn’s disease (CD) and ulcerative colitis (UC). Both are characterized by recurrent inflammation of the gastrointestinal tract, although they present distinct anatomical, histological, and clinical patterns. CD can affect any segment of the gastrointestinal tract, with transmural inflammation and discontinuous lesions. In contrast, UC is limited to the colon and rectum, presenting as continuous inflammation confined to the mucosa and submucosa. The etiology of IBD is multifactorial, involving genetic predisposition, environmental factors, alterations in the gut microbiota, and dysfunctions of innate and adaptive immune responses.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5005</offset><text>One of the most clinically relevant aspects of IBD, especially during active inflammatory phases, is the development of anemia, which affects between 30% and 60% of patients throughout the disease course. This condition is generally multifactorial, resulting from iron deficiency—caused by intestinal bleeding and malabsorption—and anemia of inflammation (also known as anemia of chronic disease), which is mediated by immunoinflammatory mechanisms.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5459</offset><text>In this context, hepcidin stands out as a key peptide hormone regulating iron metabolism. Primarily produced by hepatocytes, hepcidin is encoded by the HAMP gene and functions by inhibiting iron absorption and release through the degradation of ferroportin—the only known iron-exporting protein located on the membranes of enterocytes, macrophages, and hepatocytes. Under inflammatory conditions, particularly mediated by interleukin-6 (IL-6), hepcidin production is increased, thereby reducing systemic iron bioavailability and contributing to the persistence of anemia despite oral iron supplementation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6067</offset><text>Studies have demonstrated that hepcidin levels are significantly elevated in patients with active IBD compared to those in remission or healthy individuals. Beyond its pathophysiological role, hepcidin has been investigated as a promising biomarker to differentiate iron-deficiency anemia from anemia of inflammation, and it is also considered a potential therapeutic target in interventions aimed at restoring iron homeostasis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6496</offset><text>In addition to its role as a central regulator of iron metabolism, hepcidin is also an acute-phase reactant, with levels that increase in response to systemic inflammation and various comorbid conditions, including chronic kidney disease, infections, and obesity. These factors may confound the interpretation of hepcidin concentrations in IBD patients. It is essential to consider not only disease activity but also the broader inflammatory and metabolic context when evaluating hepcidin as a biomarker.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7001</offset><text>Therefore, considering the clinical importance of anemia in IBD and the central role of hepcidin in this process, the present work proposes a systematic review (SR) of the literature to critically compile and analyze available evidence regarding hepcidin regulation in patients with IBD. The aim is to systematically review and synthesize the evidence on the correlation between serum hepcidin levels and disease activity in patients with IBD, and to evaluate its utility as a biomarker for differentiating anemia subtypes and guiding iron therapy. We present this article in accordance with the PRISMA reporting checklist (available at https://tgh.amegroups.com/article/view/10.21037/tgh-25-99/rc).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_1</infon><offset>7701</offset><text>Methods</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>7709</offset><text>Study design</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>7722</offset><text>This SR aims to quantitatively synthesize evidence regarding: (I) correlations between hepcidin levels, inflammatory activity, and iron parameters; (II) hepcidin’s utility in differentiating anemia types; (III) its predictive value for iron therapy response in IBD patients. The investigation was conducted based on a structured methodology consisting of the following steps: delimitation of the research question, selection of databases to be consulted, definition of the search period, identification of the question components and descriptors used, execution of broad and systematic searches, establishment of inclusion and exclusion criteria, data extraction, screening of identified studies, assessment of article eligibility, and final application of exclusion criteria.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>8501</offset><text>Research strategy, screening, and data extraction</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>8551</offset><text>Prospective Register of Systematic Reviews (PROSPERO) is the leading platform for registering SR in the health field, aiming to minimize duplication of efforts and optimize the use of time and resources through transparency and prior planning of review. Initially, the platform was consulted to identify whether any SR had already been conducted on the same topic. As none were found, the review was registered on the platform and assigned the identification number CRD42024375586.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>9033</offset><text>The Rayyan software, developed by the Qatar Computing Research Institute (QCRI), was employed as a support tool for screening, organizing, and extracting data from the studies included in the present SR. The database search process commenced in November 2022 and was completed in July 2024, yielding a total of 342 published articles. Study selection was conducted autonomously and independently by two reviewers using the Rayyan system. In cases of disagreement between reviewers, a third evaluator was responsible for resolving conflicts and issuing the final decision regarding the inclusion or exclusion of studies. The databases used in this study were PubMed, PubMed PMC, BVS/BIREME, Scopus, Web of Science, Embase, EBSCOhost, and ProQuest (Table 1).</text></passage><passage><infon key="file">t1.xml</infon><infon key="id">t1</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>9790</offset><text>Database, descriptors, and free terms utilized in the systematic review</text></passage><passage><infon key="file">t1.xml</infon><infon key="id">t1</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;17.58%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;29.74%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;25.16%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;27.52%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; colspan=&quot;1&quot;&gt;Database&lt;/th&gt;&lt;th rowspan=&quot;2&quot; valign=&quot;middle&quot; align=&quot;center&quot; scope=&quot;col&quot; colspan=&quot;1&quot;&gt;Subject vocabulary&lt;/th&gt;&lt;th valign=&quot;middle&quot; colspan=&quot;2&quot; align=&quot;center&quot; scope=&quot;colgroup&quot; style=&quot;border-bottom: solid 0.50pt&quot; rowspan=&quot;1&quot;&gt;Descriptors and free terms used in the search strategy&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; colspan=&quot;1&quot; align=&quot;center&quot; scope=&quot;colgroup&quot; style=&quot;border-top: solid 0.50pt&quot; rowspan=&quot;1&quot;&gt;1&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; scope=&quot;col&quot; style=&quot;border-top: solid 0.50pt&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;2&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PubMed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MeSH &lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;PubMed PMC&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MeSH&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BVS/BIREM&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;DeCS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;EBSCOhost&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;–&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Scopus&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MeSH&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Web of Science&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MeSH&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Embase&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Emtree&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidin”, “Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;–&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ProQuest&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;MeSH &lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Hepcidins”&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;“Inflammatory Bowel Diseases”&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>9862</offset><text>Database	Subject vocabulary	Descriptors and free terms used in the search strategy	 	1	2	 	PubMed	MeSH 	“Hepcidins”	“Inflammatory Bowel Diseases”	 	PubMed PMC	MeSH	“Hepcidins”	“Inflammatory Bowel Diseases”	 	BVS/BIREM	DeCS	“Hepcidins”	“Inflammatory Bowel Diseases”	 	EBSCOhost	–	“Hepcidins”	“Inflammatory Bowel Diseases”	 	Scopus	MeSH	“Hepcidins”	“Inflammatory Bowel Diseases”	 	Web of Science	MeSH	“Hepcidins”	“Inflammatory Bowel Diseases”	 	Embase	Emtree	“Hepcidin”, “Hepcidins”	–	 	ProQuest	MeSH 	“Hepcidins”	“Inflammatory Bowel Diseases”	 	</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>10475</offset><text>Inclusion and exclusion criteria</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>10508</offset><text>We included original studies that investigated hepcidin in the context of IBD. Eligible designs encompassed: (I) human observational studies (adult and pediatric populations); (II) experimental studies using animal models of colitis; and (III) interventional studies that assessed therapeutic modulation of hepcidin or its downstream effects. The rationale for this broad inclusion was to capture the full spectrum of available evidence, ranging from mechanistic insights to clinical applications. Exclusion criteria were: (I) studies without a clear diagnosis of IBD; (II) studies in humans without IBD; (III) systematic or narrative reviews, meta-analyses, editorials, or expert opinions; and (IV) conference abstracts without sufficient primary data.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11262</offset><text>Both free-text terms and controlled descriptors were employed in constructing the search strategy, encompassing various linguistic variations. Among the free-text terms used, “Hepcidins” and “Inflammatory Bowel Disease” were prominent. The descriptors included: “hepcidinas,” “Hepcidins”, “Hepcidines”, “Doenças Inflamatórias Intestinais”, “Enfermedades Inflamatorias del Intestino”, and “Maladies inflammatoires intestinales”.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>11724</offset><text>The combination of terms was structured using Boolean operators (“OR” and “AND”) to maximize search sensitivity and ensure comprehensive retrieval of relevant literature. Thus, the applied search strategy was as follows: (Hepcidins OR “Liver-Expressed Antimicrobial Peptide” OR “Antimicrobial Peptide, Liver-Expressed” OR “Liver Expressed Antimicrobial Peptide” OR “Peptide, Liver-Expressed Antimicrobial” OR Hepcidin OR Prohepcidin OR “Pro-Hepcidin” OR “Pro Hepcidin”) AND (“Inflammatory Bowel Diseases” OR “Inflammatory Bowel Disease” OR “Bowel Diseases, Inflammatory”).</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12341</offset><text>The PICO methodology (Patient/Problem, Intervention, Comparison, and Outcome) was employed as a structuring tool to formulate the research question and guide the selection of studies included in this SR. This approach enables clear delimitation of the essential elements of the research question, promoting objectivity in the search and data analysis. Based on this framework, the guiding research question was: “What is the evidence on hepcidin expression, regulation, and clinical utility in patients with IBD, and how does it relate to inflammation, iron status, and therapeutic interventions?”</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>12943</offset><text>Following study selection, all included articles were systematically classified based on their fundamental design (e.g., cross-sectional, case-control, longitudinal, interventional, or experimental animal study) and population characteristics to facilitate a structured analysis and interpretation of the evidence level (Table 2). These categories were not predefined but were developed inductively during synthesis, based on the most recurrent themes identified across the included studies. This approach was adopted to optimize organization, highlight common findings, and facilitate interpretation of the heterogeneous body of evidence.</text></passage><passage><infon key="file">t2.xml</infon><infon key="id">t2</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>13583</offset><text>Classification and key characteristics of included studies</text></passage><passage><infon key="file">t2.xml</infon><infon key="id">t2</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;13.71%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.01%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;18.76%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;20.01%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;32.51%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Author, year&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study design&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Population/model&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Main focus/outcome measured&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Key findings&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Human studies&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Arnold &lt;italic&gt;et al.&lt;/italic&gt;, 2009 &lt;xref rid=&quot;r12&quot; ref-type=&quot;bibr&quot;&gt;12&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Case-control&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (CD, UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin &lt;italic&gt;vs.&lt;/italic&gt; inflammation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Elevated hepcidin in active IBD; correlation with IL-6&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Basseri &lt;italic&gt;et al.&lt;/italic&gt;, 2013 &lt;xref rid=&quot;r13&quot; ref-type=&quot;bibr&quot;&gt;13&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cross-sectional&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (CD)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin in anemia of inflammation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin is a key mediator of anemia in CD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Bergamaschi &lt;italic&gt;et al.&lt;/italic&gt;, 2013 &lt;xref rid=&quot;r14&quot; ref-type=&quot;bibr&quot;&gt;14&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cross-sectional&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (CD, UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin-25 for anemia differentiation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Useful to differentiate IDA from ACD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Semrin &lt;italic&gt;et al.&lt;/italic&gt;, 2006 &lt;xref rid=&quot;r15&quot; ref-type=&quot;bibr&quot;&gt;15&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cross-sectional&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric (CD, UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Urinary hepcidin and iron absorption&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Inverse correlation between urinary hepcidin and iron absorption in active IBD&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Mecklenburg &lt;italic&gt;et al.&lt;/italic&gt;, 2014 &lt;xref rid=&quot;r16&quot; ref-type=&quot;bibr&quot;&gt;16&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cross-sectional&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (CD, UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin correlation with ferritin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin strongly correlates with ferritin; iron deficiency may be a primary regulator&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Ammar &lt;italic&gt;et al.&lt;/italic&gt;, 2022 &lt;xref rid=&quot;r17&quot; ref-type=&quot;bibr&quot;&gt;17&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Diagnostic accuracy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum hepcidin for anemia diagnosis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin &amp;lt;15 ng/mL identifies IDA (Sens 88%, Spec 92%)&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Rampton &lt;italic&gt;et al.&lt;/italic&gt;, 2017 &lt;xref rid=&quot;r18&quot; ref-type=&quot;bibr&quot;&gt;18&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Interventional (open-label trial)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult &amp;amp; adolescent (IBD)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Predictors of oral iron response&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;A baseline hepcidin level &amp;gt;20 ng/mL predicts a poor response to oral iron&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Atkinson &lt;italic&gt;et al.&lt;/italic&gt;, 2018 &lt;xref rid=&quot;r19&quot; ref-type=&quot;bibr&quot;&gt;19&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Longitudinal&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric (CD)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect of anti-TNF therapy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Anti-TNF therapy reduces hepcidin levels and increases hemoglobin levels&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Loveikyte &lt;italic&gt;et al.&lt;/italic&gt;, 2023 &lt;xref rid=&quot;r20&quot; ref-type=&quot;bibr&quot;&gt;20&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Longitudinal&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (CD, UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin during biologic induction&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin is regulated by iron status even during active inflammation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Karaskova &lt;italic&gt;et al.&lt;/italic&gt;, 2020 &lt;xref rid=&quot;r21&quot; ref-type=&quot;bibr&quot;&gt;21&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Longitudinal&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric (CD, UC)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin changes with treatment&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IBD treatment reduces hepcidin levels&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot;&gt;Experimental studies&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Wang &lt;italic&gt;et al.&lt;/italic&gt;, 2012 &lt;xref rid=&quot;r22&quot; ref-type=&quot;bibr&quot;&gt;22&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental (DSS colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mouse model&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BMP/IL-6 pathway inhibition&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BMP inhibitor reduced hepcidin, increased serum iron, and attenuated colitis&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Gotardo &lt;italic&gt;et al.&lt;/italic&gt; 2014 &lt;xref rid=&quot;r23&quot; ref-type=&quot;bibr&quot;&gt;23&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental (TNBS colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Rat model&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Local hepcidin expression&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Colitis increases colonic hepcidin via IL-6/STAT3 signaling, leading to local iron accumulation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Bessman &lt;italic&gt;et al.&lt;/italic&gt;, 2020 &lt;xref rid=&quot;r24&quot; ref-type=&quot;bibr&quot;&gt;24&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental (DSS colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mouse model&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Dendritic cell-derived hepcidin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Dendritic cell-produced hepcidin sequesters iron, promoting mucosal healing&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Zhao &lt;italic&gt;et al.&lt;/italic&gt;, 2020 &lt;xref rid=&quot;r25&quot; ref-type=&quot;bibr&quot;&gt;25&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental (DSS colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mouse model&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Iron-enriched probiotics&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Probiotic Lactobacillus NKU556 reduced hepcidin and increased iron absorption&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;   Toblli &lt;italic&gt;et al.&lt;/italic&gt;, 2015 &lt;xref rid=&quot;r26&quot; ref-type=&quot;bibr&quot;&gt;26&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Experimental (DSS colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Rat model&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Iron formulation comparison&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Iron polymaltose complex was less pro-inflammatory than ferrous sulfate&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>13642</offset><text>Author, year	Study design	Population/model	Main focus/outcome measured	Key findings	 	Human studies					 	   Arnold et al., 2009 	Case-control	Adult (CD, UC)	Hepcidin vs. inflammation	Elevated hepcidin in active IBD; correlation with IL-6	 	   Basseri et al., 2013 	Cross-sectional	Adult (CD)	Hepcidin in anemia of inflammation	Hepcidin is a key mediator of anemia in CD	 	   Bergamaschi et al., 2013 	Cross-sectional	Adult (CD, UC)	Hepcidin-25 for anemia differentiation	Useful to differentiate IDA from ACD	 	   Semrin et al., 2006 	Cross-sectional	Pediatric (CD, UC)	Urinary hepcidin and iron absorption	Inverse correlation between urinary hepcidin and iron absorption in active IBD	 	   Mecklenburg et al., 2014 	Cross-sectional	Adult (CD, UC)	Hepcidin correlation with ferritin	Hepcidin strongly correlates with ferritin; iron deficiency may be a primary regulator	 	   Ammar et al., 2022 	Diagnostic accuracy	Adult (UC)	Serum hepcidin for anemia diagnosis	Hepcidin &lt;15 ng/mL identifies IDA (Sens 88%, Spec 92%)	 	   Rampton et al., 2017 	Interventional (open-label trial)	Adult &amp; adolescent (IBD)	Predictors of oral iron response	A baseline hepcidin level &gt;20 ng/mL predicts a poor response to oral iron	 	   Atkinson et al., 2018 	Longitudinal	Pediatric (CD)	Effect of anti-TNF therapy	Anti-TNF therapy reduces hepcidin levels and increases hemoglobin levels	 	   Loveikyte et al., 2023 	Longitudinal	Adult (CD, UC)	Hepcidin during biologic induction	Hepcidin is regulated by iron status even during active inflammation	 	   Karaskova et al., 2020 	Longitudinal	Pediatric (CD, UC)	Hepcidin changes with treatment	IBD treatment reduces hepcidin levels	 	Experimental studies				 	   Wang et al., 2012 	Experimental (DSS colitis)	Mouse model	BMP/IL-6 pathway inhibition	BMP inhibitor reduced hepcidin, increased serum iron, and attenuated colitis	 	   Gotardo et al. 2014 	Experimental (TNBS colitis)	Rat model	Local hepcidin expression	Colitis increases colonic hepcidin via IL-6/STAT3 signaling, leading to local iron accumulation	 	   Bessman et al., 2020 	Experimental (DSS colitis)	Mouse model	Dendritic cell-derived hepcidin	Dendritic cell-produced hepcidin sequesters iron, promoting mucosal healing	 	   Zhao et al., 2020 	Experimental (DSS colitis)	Mouse model	Iron-enriched probiotics	Probiotic Lactobacillus NKU556 reduced hepcidin and increased iron absorption	 	   Toblli et al., 2015 	Experimental (DSS colitis)	Rat model	Iron formulation comparison	Iron polymaltose complex was less pro-inflammatory than ferrous sulfate	 	</text></passage><passage><infon key="file">t2.xml</infon><infon key="id">t2</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>16231</offset><text>ACD, anemia of chronic disease; BMP, bone morphogenetic protein; CD, Crohn’s disease; DSS, dextran sodium sulfate; IBD, inflammatory bowel disease; IDA, iron deficiency anemia; IL-6, interleukin-6; TNBS, trinitrobenzenesulfonic acid; TNF, tumor necrosis factor; UC, ulcerative colitis.</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">title_2</infon><offset>16519</offset><text>Risk of bias assessment</text></passage><passage><infon key="section_type">METHODS</infon><infon key="type">paragraph</infon><offset>16543</offset><text>The methodological quality and risk of bias of the included studies were assessed using study-design–appropriate tools. For observational studies, the Newcastle–Ottawa Scale (NOS) and the ROBINS-I (Risk of Bias in Non-randomized Studies of Interventions) tool were applied to evaluate selection, comparability, and outcome domains. For randomized controlled trials (RCTs), the Cochrane Risk of Bias 2.0 (RoB 2) tool was used to assess randomization, allocation concealment, blinding, and outcome reporting. For experimental animal studies, the SYRCLE’s Risk of Bias tool was employed to ensure methodological rigor and transparency. All assessments were performed independently by two reviewers, and discrepancies were resolved by consensus or by consultation with a third reviewer.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_1</infon><offset>17332</offset><text>Results</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17340</offset><text>The search strategy was conducted across eight databases, with the last update performed on June 6, 2024. Initially, 872 articles published between 2003 and 2024 were identified, of which 530 were excluded due to duplication, leading to 342 studies (Figure 1).</text></passage><passage><infon key="file">tgh-11-25-99-f1.jpg</infon><infon key="id">f1</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>17601</offset><text>PRISMA flow diagram illustrating the process of identification, screening, eligibility assessment, and inclusion of studies in the review. The figure shows the number of records identified from databases and registers, records excluded at each stage, and the total number of studies included in the final analysis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>17916</offset><text>Specifically, 81 articles were retrieved from PubMed; 19 from PubMed Central (PMC); 83 through BVS/BIREME (MEDLINE: 81, LILACS: 1, WPRIM: 1); 101 via the EBSCOhost platform; 166 from Scopus; 134 from Web of Science; 261 from Embase; and 27 from ProQuest. After duplicate removal, 342 articles remained for title and abstract screening, aiming to identify studies aligned with the objectives of the present review.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18330</offset><text>Subsequently, the following steps of the selection flowchart were applied, resulting in 47 studies that met the inclusion criteria and were deemed relevant for interpretative analysis. All articles included in this SR were published in English, although they were conducted in various countries.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>18626</offset><text>These studies were grouped post-selection to optimize organization and extraction of relevant information for the study. The thematic groups were: “The role of hepcidin in the pathophysiology of IBD”, “Hepcidin and inflammation in IBD: implications for disease mechanisms”, “Emerging therapeutic targets involving hepcidin in IBD”, “Hepcidin as a biomarker for IBD assessment”, and “Effect of IBD treatment on hepcidin regulation”.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>19078</offset><text>Hepcidin and inflammation in IBD: pathophysiological implications</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19144</offset><text>The synthesized evidence from human studies demonstrates that inflammatory signals predominantly regulate hepcidin. Specifically, serum hepcidin levels show a strong positive correlation with interleukin-6 (IL-6) (r=0.85, P&lt;0.01) and C-reactive protein (CRP) (r=0.72, P&lt;0.01) in patients with active CD, confirming its role as an inflammation-induced hormone. Active inflammation increases hepcidin levels, reducing iron absorption and mobilization and contributing to anemia.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>19621</offset><text>While inflammation is a primary driver of hepcidin elevation, the articles identified in our SR showed specific clinical scenarios in which the regulatory effects of erythropoietic demand and iron deficiency can override the inflammatory stimulus. This was particularly evident in patients with severe iron-deficiency anemia, in whom the potent erythropoietic signal mediated by erythroferrone led to suppressed hepcidin levels despite active inflammation. Furthermore, the balance between these competing signals appears to be influenced by IBD subtype, disease phenotype, and specific therapeutic interventions such as lactoferrin supplementation, which can modulate hepcidin independently of systemic inflammatory markers.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>20347</offset><text>Conversely, in cases of severe anemia, erythropoietic stimulation may suppress hepcidin production despite ongoing inflammation. This duality underscores the central role of hepcidin at the interface between iron metabolism and inflammation. Additionally, the influence of vitamin D as a negative regulator of hepcidin is highlighted, suggesting potential complementary therapeutic strategies (Figure 2).</text></passage><passage><infon key="file">tgh-11-25-99-f2.jpg</infon><infon key="id">f2</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>20752</offset><text>Flowchart illustrating the main mechanisms involved in regulating hepcidin in patients with IBD. Systemic and local inflammatory factors, such as the cytokines IL-6 and TNF-α, as well as the gut microbiota, modulate hepcidin expression through different pathways. IL-6 stimulates the STAT3 signaling pathway, leading to increased hepcidin expression. In contrast, TNF-α acts by directly inhibiting its production, while the gut microbiota exerts variable modulation, potentially increasing or decreasing protein levels. The net hepcidin expression directly impacts intestinal absorption and systemic iron stores, thus representing a key link between inflammation and iron metabolism in IBD. Figure created with Biorender.com. IBD, inflammatory bowel disease; IL-6, interleukin-6; TNF-α, tumor necrosis factor alpha.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>21580</offset><text>Table 3 provides a synthesis of evidence from human studies examining hepcidin regulation and its pathophysiological implications in IBD. Across studies, serum and urinary hepcidin levels were consistently elevated in active disease and correlated strongly with inflammatory markers, reinforcing inflammation as a central regulatory mechanism. Elevated hepcidin was linked to anemia of inflammation through impaired iron absorption and mobilization, while hepcidin-25 emerged as a reliable biomarker for distinguishing anemia of chronic disease from iron deficiency anemia. Some evidence suggests that severe iron deficiency may attenuate hepcidin expression despite persistent inflammation, indicating the existence of competing regulatory pathways. Additionally, vitamin D supplementation was associated with reduced hepcidin levels, suggesting nutritional modulation. Tissue-level analyses further revealed differential mucosal expression between UC and CD.</text></passage><passage><infon key="file">t3.xml</infon><infon key="id">t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>22541</offset><text>Synthesis of evidence from human studies: hepcidin regulation and its pathophysiological implications in IBD</text></passage><passage><infon key="file">t3.xml</infon><infon key="id">t3</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;21.09%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;51.95%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;26.96%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Thematic category&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Key synthesized finding&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Supporting references&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Regulation by inflammation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum/urinary hepcidin levels are significantly elevated in active IBD and show a strong positive correlation with inflammatory markers (CRP, IL-6)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Arnold &lt;italic&gt;et al.&lt;/italic&gt;, 2009&lt;xref rid=&quot;r12&quot; ref-type=&quot;bibr&quot;&gt;12&lt;/xref&gt;; Basseri &lt;italic&gt;et al.&lt;/italic&gt;, 2013&lt;xref rid=&quot;r13&quot; ref-type=&quot;bibr&quot;&gt;13&lt;/xref&gt;; Semrin &lt;italic&gt;et al.&lt;/italic&gt;, 2006 &lt;xref rid=&quot;r25&quot; ref-type=&quot;bibr&quot;&gt;25&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Role in anemia pathogenesis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Elevated hepcidin is a key mediator of anemia of inflammation in IBD, leading to functional iron deficiency via impaired iron absorption and mobilization&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Basseri &lt;italic&gt;et al.&lt;/italic&gt;, 2013&lt;xref rid=&quot;r13&quot; ref-type=&quot;bibr&quot;&gt;13&lt;/xref&gt;; Bergamaschi &lt;italic&gt;et al.&lt;/italic&gt;, 2013 &lt;xref rid=&quot;r14&quot; ref-type=&quot;bibr&quot;&gt;14&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Differentiating anemia types&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin-25 is a useful biomarker for differentiating ACD from IDA, with low levels indicating true iron deficiency&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bergamaschi &lt;italic&gt;et al.&lt;/italic&gt;, 2013&lt;xref rid=&quot;r14&quot; ref-type=&quot;bibr&quot;&gt;14&lt;/xref&gt;; Martinelli &lt;italic&gt;et al.&lt;/italic&gt;, 2016 &lt;xref rid=&quot;r27&quot; ref-type=&quot;bibr&quot;&gt;27&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Competing regulation: iron deficiency &lt;italic&gt;vs.&lt;/italic&gt; inflammation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;In states of severe iron deficiency, the erythropoietic drive can override inflammation, leading to suppressed hepcidin levels despite active disease&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mecklenburg &lt;italic&gt;et al.&lt;/italic&gt;, 2014 &lt;xref rid=&quot;r16&quot; ref-type=&quot;bibr&quot;&gt;16&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Impact of nutritional status&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Vitamin D supplementation is associated with reduced hepcidin levels, suggesting a role in modulating iron availability&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Moran-Lev &lt;italic&gt;et al.&lt;/italic&gt;, 2019&lt;xref rid=&quot;r28&quot; ref-type=&quot;bibr&quot;&gt;28&lt;/xref&gt;; Stallhofer &lt;italic&gt;et al.&lt;/italic&gt;, 2022 &lt;xref rid=&quot;r29&quot; ref-type=&quot;bibr&quot;&gt;29&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Local expression in gut mucosa&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin is expressed locally in the colonic epithelium and is differentially regulated in UC compared to CD&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Li &lt;italic&gt;et al.&lt;/italic&gt;, 2016 &lt;xref rid=&quot;r30&quot; ref-type=&quot;bibr&quot;&gt;30&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Correlation with iron transporters&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Inflammation in IBD is associated with decreased duodenal ferroportin expression, consistent with hepcidin-mediated degradation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Burpee &lt;italic&gt;et al.&lt;/italic&gt;, 2011&lt;xref rid=&quot;r31&quot; ref-type=&quot;bibr&quot;&gt;31&lt;/xref&gt;; Oustamanolakis &lt;italic&gt;et al.&lt;/italic&gt;, 2011 &lt;xref rid=&quot;r32&quot; ref-type=&quot;bibr&quot;&gt;32&lt;/xref&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>22650</offset><text>Thematic category	Key synthesized finding	Supporting references	 	Regulation by inflammation	Serum/urinary hepcidin levels are significantly elevated in active IBD and show a strong positive correlation with inflammatory markers (CRP, IL-6)	Arnold et al., 2009; Basseri et al., 2013; Semrin et al., 2006 	 	Role in anemia pathogenesis	Elevated hepcidin is a key mediator of anemia of inflammation in IBD, leading to functional iron deficiency via impaired iron absorption and mobilization	Basseri et al., 2013; Bergamaschi et al., 2013 	 	Differentiating anemia types	Hepcidin-25 is a useful biomarker for differentiating ACD from IDA, with low levels indicating true iron deficiency	Bergamaschi et al., 2013; Martinelli et al., 2016 	 	Competing regulation: iron deficiency vs. inflammation	In states of severe iron deficiency, the erythropoietic drive can override inflammation, leading to suppressed hepcidin levels despite active disease	Mecklenburg et al., 2014 	 	Impact of nutritional status	Vitamin D supplementation is associated with reduced hepcidin levels, suggesting a role in modulating iron availability	Moran-Lev et al., 2019; Stallhofer et al., 2022 	 	Local expression in gut mucosa	Hepcidin is expressed locally in the colonic epithelium and is differentially regulated in UC compared to CD	Li et al., 2016 	 	Correlation with iron transporters	Inflammation in IBD is associated with decreased duodenal ferroportin expression, consistent with hepcidin-mediated degradation	Burpee et al., 2011; Oustamanolakis et al., 2011 	 	</text></passage><passage><infon key="file">t3.xml</infon><infon key="id">t3</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>24195</offset><text>ACD, anemia of chronic disease; CD, Crohn’s disease; CRP, C-reactive protein; IBD, inflammatory bowel disease; IDA, iron deficiency anemia; IL-6, interleukin-6; UC, ulcerative colitis.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>24382</offset><text>Animal model studies involving hepcidin</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>24422</offset><text>Experimental data obtained from animal models of induced colitis provide direct comparisons of the effects of different iron formulations (Table 4). In a DSS-induced colitis model, ferrous sulfate significantly aggravated intestinal inflammation, increasing colonic IL-6 by 3.5-fold and elevating systemic markers of oxidative stress compared to untreated controls. In contrast, iron polymaltose complex resulted in a 50% lower inflammatory response under the same conditions, establishing it as a less pro-inflammatory alternative. In pediatric IBD, lactoferrin supplementation demonstrated dual benefits, reducing median serum hepcidin by 40% and IL-6 by 35%, and was associated with a significant increase in hemoglobin of 1.8 g/dL. These findings reinforce the multifaceted role of hepcidin in IBD and point to innovative therapeutic targets (Figure 3).</text></passage><passage><infon key="file">t4.xml</infon><infon key="id">t4</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>25280</offset><text>Effects of different iron formulations on inflammation, hepcidin, and hematological parameters in IBD</text></passage><passage><infon key="file">t4.xml</infon><infon key="id">t4</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;10.76%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;12.3%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.96%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;23.17%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.85%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;21.96%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Stud, year&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Model/population&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Intervention&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on inflammation&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on hepcidin&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on hematological parameters&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Toblli &lt;italic&gt;et al.&lt;/italic&gt;, 2015 &lt;xref rid=&quot;r26&quot; ref-type=&quot;bibr&quot;&gt;26&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;DSS-induced colitis in mice&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ferrous sulfate &lt;italic&gt;vs.&lt;/italic&gt; iron polymaltose complex&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ferrous sulfate markedly aggravated intestinal inflammation, with a 3.5-fold increase in colonic IL-6 and elevated systemic oxidative stress; iron polymaltose complex resulted in ~50% lower inflammatory response under the same conditions&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not directly assessed&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;–&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;El Amrousy &lt;italic&gt;et al.&lt;/italic&gt;, 2022 &lt;xref rid=&quot;r33&quot; ref-type=&quot;bibr&quot;&gt;33&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric IBD patients with iron-deficiency anemia&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Lactoferrin (100 mg/day, 3 months)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;35% reduction in IL-6 levels&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;40% reduction in median serum hepcidin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hemoglobin increased by 1.8 g/dL, indicating simultaneous correction of anemia and attenuation of inflammation&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>25382</offset><text>Stud, year	Model/population	Intervention	Effect on inflammation	Effect on hepcidin	Effect on hematological parameters	 	Toblli et al., 2015 	DSS-induced colitis in mice	Ferrous sulfate vs. iron polymaltose complex	Ferrous sulfate markedly aggravated intestinal inflammation, with a 3.5-fold increase in colonic IL-6 and elevated systemic oxidative stress; iron polymaltose complex resulted in ~50% lower inflammatory response under the same conditions	Not directly assessed	–	 	El Amrousy et al., 2022 	Pediatric IBD patients with iron-deficiency anemia	Lactoferrin (100 mg/day, 3 months)	35% reduction in IL-6 levels	40% reduction in median serum hepcidin	Hemoglobin increased by 1.8 g/dL, indicating simultaneous correction of anemia and attenuation of inflammation	 	</text></passage><passage><infon key="file">t4.xml</infon><infon key="id">t4</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>26155</offset><text>DSS, dextran sodium sulfate; IBD, inflammatory bowel disease; IL-6, interleukin-6.</text></passage><passage><infon key="file">tgh-11-25-99-f3.jpg</infon><infon key="id">f3</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>26238</offset><text>Flowchart illustrating the effects of different oral iron administration forms on hepcidin, intestinal inflammation, and anemia-related outcomes. Ferrous sulfate demonstrates good absorption and clinical stability in adolescents and adults. Ferric polymaltose is associated with reduced intestinal inflammation and is considered a safe therapeutic option. Maresin 1, in turn, promotes the reduction of hepcidin and inflammation, thereby contributing to the improvement of anemia. Figure created with Biorender.com.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>26753</offset><text>Hepcidin as a biomarker in the assessment of IBD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>26802</offset><text>The six studies included in the SR demonstrate the potential of hepcidin as a biomarker for assessing disease activity and monitoring anemia in IBD. Most of the publications analyzed patients with both CD and UC, including both adult and pediatric populations, highlighting variations in hepcidin levels associated with inflammatory activity, iron deficiency, and different types of anemia.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>27193</offset><text>Overall, hepcidin proved useful in differentiating iron deficiency anemia (IDA) from anemia of chronic disease (ACD), although its standalone accuracy varies. Notably, the combined use of hepcidin with other biomarkers, such as reticulocyte hemoglobin content (CHr), soluble transferrin receptor (sTfR), and ferritin, was emphasized to provide a more robust evaluation of iron status.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>27578</offset><text>Furthermore, results suggest that hepcidin may reflect both inflammatory status and iron stores, being particularly relevant for individualizing anemia treatment in patients with IBD (Figure 4).</text></passage><passage><infon key="file">tgh-11-25-99-f4.jpg</infon><infon key="id">f4</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>27773</offset><text>Flowchart illustrating the role of hepcidin as a differential biomarker in anemia types among IBD patients. Serum hepcidin measurement may indicate two main profiles: decreased levels (hepcidin ↓), typically associated with iron deficiency anemia, and increased levels (hepcidin ↑), characteristic of anemia of inflammation. The positive correlation between hepcidin and ferritin supports its use as a marker of iron metabolism. These findings suggest that hepcidin may serve as a complementary tool for therapeutic decision-making, particularly in guiding the use of iron supplementation or anti-inflammatory treatments. Figure created with Biorender.com. IBD, inflammatory bowel disease.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>28467</offset><text>Table 5 outlines methodological heterogeneity across included studies, highlighting key differences in the biological matrix, analyte form, and assay techniques used for hepcidin quantification. Most studies measured hepcidin-25 in serum using enzyme-linked immunosorbent assay (ELISA), while others employed alternative approaches such as RIA, LC-MS/MS, or mass spectrometry. A minority of subjects were assessed for prohepcidin or urinary hepcidin, introducing further variability. Reference ranges and clinical cut-offs were inconsistently reported, limiting inter-study comparability. Notably, some studies demonstrated strong correlations between serum hepcidin and inflammatory markers (IL-6, CRP), while others emphasized its clinical utility in specific populations or contexts, such as anemia of inflammation or treatment response. This methodological diversity underscores the need for assay standardization to enhance reproducibility and facilitate cross-study synthesis.</text></passage><passage><infon key="file">t5.xml</infon><infon key="id">t5</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>29450</offset><text>Assay and matrix heterogeneity among included studies</text></passage><passage><infon key="file">t5.xml</infon><infon key="id">t5</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;17.23%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;8.04%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;12.64%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;13.8%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;10.35%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;17.24%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;20.7%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Author, year&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Matrix&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Analyte measured&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Assay method&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;center&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Units&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Reference range/cut-off (if reported)&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Notes&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Basseri, 2013 &lt;xref rid=&quot;r13&quot; ref-type=&quot;bibr&quot;&gt;13&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin-25&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ng/mL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not reported&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Strong correlation with IL-6, CRP&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Semrin, 2006 &lt;xref rid=&quot;r15&quot; ref-type=&quot;bibr&quot;&gt;15&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Urine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;RIA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ng/mg creatinine&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not reported&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Associated with malabsorption&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Nagy, 2010 &lt;xref rid=&quot;r34&quot; ref-type=&quot;bibr&quot;&gt;34&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Prohepcidin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ng/mL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not reported&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Weak correlation with inflammation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Bergamaschi, 2013 &lt;xref rid=&quot;r14&quot; ref-type=&quot;bibr&quot;&gt;14&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin-25&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mass spectrometry&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;nmol/L&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Cut-off 20 nmol/L (anemia of inflammation)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Suggested clinical utility&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Karaskova, 2018 &lt;xref rid=&quot;r21&quot; ref-type=&quot;bibr&quot;&gt;21&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin-25&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ELISA&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ng/mL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric reference range reported&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Population-specific values&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Loveikyte, 2023 &lt;xref rid=&quot;r20&quot; ref-type=&quot;bibr&quot;&gt;20&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Serum&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin-25&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LC-MS/MS&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;center&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;ng/mL&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Not reported&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Evaluated response to biologics&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>29504</offset><text>Author, year	Matrix	Analyte measured	Assay method	Units	Reference range/cut-off (if reported)	Notes	 	Basseri, 2013 	Serum	Hepcidin-25	ELISA	ng/mL	Not reported	Strong correlation with IL-6, CRP	 	Semrin, 2006 	Urine	Hepcidin	RIA	ng/mg creatinine	Not reported	Associated with malabsorption	 	Nagy, 2010 	Serum	Prohepcidin	ELISA	ng/mL	Not reported	Weak correlation with inflammation	 	Bergamaschi, 2013 	Serum	Hepcidin-25	Mass spectrometry	nmol/L	Cut-off 20 nmol/L (anemia of inflammation)	Suggested clinical utility	 	Karaskova, 2018 	Serum	Hepcidin-25	ELISA	ng/mL	Pediatric reference range reported	Population-specific values	 	Loveikyte, 2023 	Serum	Hepcidin-25	LC-MS/MS	ng/mL	Not reported	Evaluated response to biologics	 	</text></passage><passage><infon key="file">t5.xml</infon><infon key="id">t5</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>30230</offset><text>CRP, C-reactive protein; ELISA, enzyme-linked immunosorbent assay; IL-6, interleukin-6; LC-MS/MS, liquid chromatography-tandem mass spectrometry; RIA, radioimmunoassay.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>30399</offset><text>Effect of IBD treatment on hepcidin regulation</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>30446</offset><text>Clinical studies provide evidence that effective anti-inflammatory therapy directly modulates hepcidin. The analysis of studies evaluating therapeutic interventions in IBD revealed that anti-inflammatory treatments, such as anti-TNF-α agents, and iron supplementation—including lactoferrin and sucrosomial iron—directly impact serum hepcidin levels (Table 6).</text></passage><passage><infon key="file">t6.xml</infon><infon key="id">t6</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>30811</offset><text>Effects of therapeutic interventions on hepcidin regulation in patients with inflammatory bowel disease</text></passage><passage><infon key="file">t6.xml</infon><infon key="id">t6</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;12.2%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.56%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;16.67%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;17.78%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;17.78%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;20.01%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study, year&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Model/population&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Intervention/treatment&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on inflammation&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on hepcidin&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on hematological parameters&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Atkinson &lt;italic&gt;et al.&lt;/italic&gt;, 2018 &lt;xref rid=&quot;r19&quot; ref-type=&quot;bibr&quot;&gt;19&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric (Crohn’s disease)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Anti-TNF-α therapy (infliximab)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Significant reduction in inflammatory markers (IL-6, CRP) after induction therapy&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Approximately 45% decrease in median serum hepcidin levels&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mean hemoglobin increase of 1.8 g/dL; correction of inflammation-associated anemia&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Karaskova &lt;italic&gt;et al.&lt;/italic&gt;, 2020 &lt;xref rid=&quot;r21&quot; ref-type=&quot;bibr&quot;&gt;21&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric (Crohn’s disease and ulcerative colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Conventional therapy (corticosteroids and immunomodulators)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gradual reduction in IL-6 and CRP levels during treatment&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Progressive decrease in serum hepcidin levels&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Improvement in hematological indices over time&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Loveikyte &lt;italic&gt;et al.&lt;/italic&gt;, 2023 &lt;xref rid=&quot;r20&quot; ref-type=&quot;bibr&quot;&gt;20&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult (Crohn’s disease and ulcerative colitis)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Biologic induction (anti-TNF, anti-integrin, anti-IL-12/23 agents)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Significant reduction in disease activity&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hepcidin is mainly regulated by iron status even under residual inflammation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Increase in hemoglobin and ferritin, indicating improved iron metabolism&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;El Amrousy &lt;italic&gt;et al.&lt;/italic&gt;, 2022 &lt;xref rid=&quot;r33&quot; ref-type=&quot;bibr&quot;&gt;33&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Pediatric IBD with iron-deficiency anemia&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Oral lactoferrin (100 mg/day for 3 months)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;~35% reduction in IL-6 levels&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;~40% decrease in median serum hepcidin&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Hemoglobin increased by 1.8 g/dL; simultaneous improvement in anemia and inflammation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Rampton &lt;italic&gt;et al.&lt;/italic&gt;, 2017 &lt;xref rid=&quot;r18&quot; ref-type=&quot;bibr&quot;&gt;18&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Adult and adolescent IBD patients&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Oral iron supplementation&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Patients with high baseline hepcidin showed a stronger inflammatory response&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Baseline hepcidin &amp;gt;20 ng/mL predicted poor response to oral iron&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Incomplete anemia correction in patients with elevated hepcidin&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Shu &lt;italic&gt;et al.&lt;/italic&gt;, 2019 (&lt;italic&gt;in vitro&lt;/italic&gt;) &lt;xref rid=&quot;r35&quot; ref-type=&quot;bibr&quot;&gt;35&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Human hepatocyte model&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;TNF-α/NF-κB pathway blockade (monoclonal antibody)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Suppression of TNF-α-dependent inflammatory signaling&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Downregulation of hepatic hepcidin gene expression&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mechanistic explanation for the anti-TNF effect on iron metabolism restoration&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>30915</offset><text>Study, year	Model/population	Intervention/treatment	Effect on inflammation	Effect on hepcidin	Effect on hematological parameters	 	Atkinson et al., 2018 	Pediatric (Crohn’s disease)	Anti-TNF-α therapy (infliximab)	Significant reduction in inflammatory markers (IL-6, CRP) after induction therapy	Approximately 45% decrease in median serum hepcidin levels	Mean hemoglobin increase of 1.8 g/dL; correction of inflammation-associated anemia	 	Karaskova et al., 2020 	Pediatric (Crohn’s disease and ulcerative colitis)	Conventional therapy (corticosteroids and immunomodulators)	Gradual reduction in IL-6 and CRP levels during treatment	Progressive decrease in serum hepcidin levels	Improvement in hematological indices over time	 	Loveikyte et al., 2023 	Adult (Crohn’s disease and ulcerative colitis)	Biologic induction (anti-TNF, anti-integrin, anti-IL-12/23 agents)	Significant reduction in disease activity	Hepcidin is mainly regulated by iron status even under residual inflammation	Increase in hemoglobin and ferritin, indicating improved iron metabolism	 	El Amrousy et al., 2022 	Pediatric IBD with iron-deficiency anemia	Oral lactoferrin (100 mg/day for 3 months)	~35% reduction in IL-6 levels	~40% decrease in median serum hepcidin	Hemoglobin increased by 1.8 g/dL; simultaneous improvement in anemia and inflammation	 	Rampton et al., 2017 	Adult and adolescent IBD patients	Oral iron supplementation	Patients with high baseline hepcidin showed a stronger inflammatory response	Baseline hepcidin &gt;20 ng/mL predicted poor response to oral iron	Incomplete anemia correction in patients with elevated hepcidin	 	Shu et al., 2019 (in vitro) 	Human hepatocyte model	TNF-α/NF-κB pathway blockade (monoclonal antibody)	Suppression of TNF-α-dependent inflammatory signaling	Downregulation of hepatic hepcidin gene expression	Mechanistic explanation for the anti-TNF effect on iron metabolism restoration	 	</text></passage><passage><infon key="file">t6.xml</infon><infon key="id">t6</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>32838</offset><text>CRP, C-reactive protein; IBD, inflammatory bowel disease; IL-6, interleukin-6; NF-κB, nuclear factor kappaB; TNF, tumor necrosis factor.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>32979</offset><text>In children with CD, anti-TNF-α therapy (infliximab) led to a 45% decrease in median hepcidin levels, paralleled by a significant increase in hemoglobin of 1.8 g/dL, directly linking inflammation control to improved iron availability.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>33218</offset><text>Inhibition of the inflammatory pathway resulted in decreased hepcidin concentrations and improved hematological parameters, particularly hemoglobin, highlighting the interdependence between inflammatory activity and iron metabolism. Interventions combining anti-inflammatory effects with iron replacement proved more effective in correcting anemia, with hepcidin serving as a useful biomarker for monitoring and predicting treatment response.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>33661</offset><text>This is mechanistically supported by in vitro data showing that anti-TNF-α monoclonal antibody therapy downregulates hepcidin expression in hepatocytes by inhibiting the TNF-α/NF-κB pathway. The cascading effects of these treatments on the inflammation-hepcidin-hemoglobin axis are depicted in Figure 5.</text></passage><passage><infon key="file">tgh-11-25-99-f5.jpg</infon><infon key="id">f5</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>33977</offset><text>Flowchart illustrating the main therapeutic effects of different strategies used in the treatment of IBD on inflammation and hepcidin regulation. The use of anti-TNF-α agents and lactoferrin reduces systemic inflammation, contributing to a decrease in hepcidin expression, which in turn favors an increase in hemoglobin levels. Additionally, lactoferrin exerts a direct effect on hepcidin regulation. Conversely, intracellular inhibitors act by reducing the activation of inflammatory pathways such as NF-κB and caspases, promoting improvement in anemia. Figure created with Biorender.com. IBD, inflammatory bowel disease; NF-κB, nuclear factor kappaB; TNF, tumor necrosis factor.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">title_2</infon><offset>34670</offset><text>Emerging therapeutic targets involving hepcidin in IBD</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>34725</offset><text>Preclinical evidence highlights the therapeutic potential of hepcidin inhibition. The studies presented in Table 7 indicate that hepcidin inhibition represents a promising strategy for managing anemia and inflammation in IBD. In a murine model of colitis, administration of a BMP6 pathway inhibitor led to a 60% reduction in hepatic hepcidin mRNA expression, improved serum iron levels, and attenuation of intestinal inflammation, demonstrating dual benefits for both iron metabolism and inflammatory activity. These findings suggest that pharmacological modulation of hepcidin or its regulatory pathways may act dually in the treatment of IBD, both correcting iron-deficiency anemia and contributing to the control of inflammatory activity.</text></passage><passage><infon key="file">t7.xml</infon><infon key="id">t7</infon><infon key="section_type">TABLE</infon><infon key="type">table_title_caption</infon><offset>35467</offset><text>Emerging therapeutic targets involving hepcidin in inflammatory bowel disease</text></passage><passage><infon key="file">t7.xml</infon><infon key="id">t7</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;hsides&quot; rules=&quot;groups&quot;&gt;&lt;col width=&quot;12.47%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;15.91%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;18.19%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;20.47%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;14.77%&quot; span=&quot;1&quot;/&gt;&lt;col width=&quot;18.19%&quot; span=&quot;1&quot;/&gt;&lt;thead&gt;&lt;tr&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Study, year&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Model/population&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Intervention/experimental approach&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Mechanism of action/pathway targeted&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on hepcidin&lt;/th&gt;&lt;th valign=&quot;middle&quot; align=&quot;left&quot; scope=&quot;col&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Effect on inflammation and iron metabolism&lt;/th&gt;&lt;/tr&gt;&lt;/thead&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; scope=&quot;row&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Wang &lt;italic&gt;et al.&lt;/italic&gt;, 2012 &lt;xref rid=&quot;r22&quot; ref-type=&quot;bibr&quot;&gt;22&lt;/xref&gt;&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Murine model of DSS-induced colitis&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;BMP6/IL-6 pathway inhibition (BMP inhibitor)&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Suppression of hepcidin transcription via BMP/SMAD signaling blockade&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;~60% reduction in hepatic hepcidin mRNA expression&lt;/td&gt;&lt;td valign=&quot;top&quot; align=&quot;left&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Increased serum iron levels and attenuation of intestinal inflammation&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>35545</offset><text>Study, year	Model/population	Intervention/experimental approach	Mechanism of action/pathway targeted	Effect on hepcidin	Effect on inflammation and iron metabolism	 	Wang et al., 2012 	Murine model of DSS-induced colitis	BMP6/IL-6 pathway inhibition (BMP inhibitor)	Suppression of hepcidin transcription via BMP/SMAD signaling blockade	~60% reduction in hepatic hepcidin mRNA expression	Increased serum iron levels and attenuation of intestinal inflammation	 	</text></passage><passage><infon key="file">t7.xml</infon><infon key="id">t7</infon><infon key="section_type">TABLE</infon><infon key="type">table_foot</infon><offset>36005</offset><text>BMP, bone morphogenetic protein; DSS, dextran sodium sulfate; IL-6, interleukin-6.</text></passage><passage><infon key="section_type">RESULTS</infon><infon key="type">paragraph</infon><offset>36088</offset><text>Only one study to date, conducted by Wang et al. [2012], has directly investigated hepcidin modulation as a therapeutic strategy in IBD using a murine colitis model. In this experimental setting, inhibition of the BMP6/IL-6 pathway reduced hepatic hepcidin expression, improved systemic iron levels, and partially attenuated intestinal inflammation. Although these findings are promising, they must be interpreted with caution, as they derive from a single preclinical study (Figure 6).</text></passage><passage><infon key="file">tgh-11-25-99-f6.jpg</infon><infon key="id">f6</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>36575</offset><text>Conceptual illustration of the potential effects of hepcidin inhibition in IBD, based on preliminary animal model evidence [Wang et al., 2012]. Reduction of hepcidin expression was associated with improved iron levels and decreased intestinal inflammation. These data are experimental and should be regarded as hypothesis-generating, highlighting the need for further translational and clinical studies before considering hepcidin modulation as a therapeutic approach. Figure created with Biorender.com. IBD, inflammatory bowel disease.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_1</infon><offset>37112</offset><text>Discussion</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>37123</offset><text>Hepcidin is a key hormone in iron regulation, whose expression increases in response to inflammation, especially under IL-6 stimulation via the JAK/STAT3 pathway. In IBD, this elevation promotes the internalization of ferroportin, reducing intestinal absorption and the release of iron from macrophage and hepatic stores, which contributes to anemia of inflammation despite adequate iron reserves.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>37521</offset><text>This systematic review synthesizes evidence from 47 studies with diverse designs, collectively clarifying the role of hepcidin in IBD. Case-control and cross-sectional studies consistently demonstrate strong correlations between hepcidin, inflammation, and anemia, while longitudinal and interventional studies support causality, showing that anti-TNF-α therapy reduces inflammation, lowers hepcidin, and improves hemoglobin levels. In contrast, few trials on iron supplementation reveal a key gap in the literature. Experimental models further reinforce these findings, identifying BMP/IL-6 signaling as a potential therapeutic target.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>38162</offset><text>Our review advances beyond mechanistic associations by providing a quantitative synthesis that establishes hepcidin’s central role at the crossroads of inflammation and iron metabolism. Elevated hepcidin in active disease and its strong correlation with CRP and IL-6 confirm its function in inflammation-driven iron sequestration. The mean negative correlation with hemoglobin (r≈–0.7) quantifies its impact on anemia, explaining functional iron deficiency despite adequate stores. Importantly, emerging thresholds provide clinical value for hepcidin measurement: levels &lt;15 ng/mL help identify iron-deficiency anemia, while &gt;20 ng/mL predict oral iron therapy failure. Incorporating hepcidin into clinical algorithms could refine anemia classification and guide targeted therapy, minimizing ineffective oral iron use and prompting timely intravenous or anti-inflammatory interventions. Conversely, situations of increased iron demand, such as iron deficiency anemia, induce the production of erythroferrone by erythroid precursors, which suppresses hepcidin and facilitates iron availability for erythropoiesis. This regulation makes hepcidin a promising biomarker to distinguish between iron deficiency anemia and anemia of chronic disease, conditions that commonly overlap in IBD. Furthermore, hepcidin expression by epithelial and immune cells in the gastrointestinal tract has also been investigated, with potential implications for local iron regulation and intestinal inflammatory response.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>39666</offset><text>Despite limitations related to assay standardization and reference value definition, hepcidin represents a crucial link between inflammation and iron metabolism, with significant clinical potential in IBD. Thus, this SR was developed to relate the available information, aiming to understand how hepcidin regulation changes in the presence of chronic intestinal inflammation and what the implications are for monitoring and managing anemia associated with IBD, thereby contributing to a more targeted approach in patient care.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>40193</offset><text>Hepcidin and inflammation in IBD: pathophysiological implications verified in human and animal experimental studies</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>40309</offset><text>Inflammatory mediators, particularly IL-6, play a significant role in regulating hepcidin. Basseri et al. [2013] and Arnold et al. [2009] demonstrated elevated hepcidin levels in patients with IBD and anemia of chronic disease, with strong correlations with IL-6 and CRP. Semrin et al. [2006] reinforced that increased urinary hepcidin is associated with iron malabsorption in patients with active IBD.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>40712</offset><text>Studies such as those by Bergamaschi et al. [2013] and Martinelli et al. [2016] have demonstrated that hepcidin-25 aids in differentiating iron deficiency anemia from ACD. In contrast, Mecklenburg et al. [2014] suggested that iron deficiency, rather than inflammation, might be the primary regulator of hepcidin in specific clinical contexts.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>41055</offset><text>Nutritional interventions, such as vitamin D supplementation, were investigated by Moran-Lev et al. [2019] and Stallhofer et al. [2022], which showed a significant reduction in hepcidin after treatment, possibly through the modulation of ceruloplasmin and intestinal iron absorption. Burpee et al. [2011] and Oustamanolakis et al. [2011] also contributed to understanding local expression of iron-regulatory proteins, such as ferroportin, in relation to hepcidin and inflammation. Finally, the metaproteomic study by Li et al. [2016] revealed that hepcidin is expressed in colonic epithelium and that its expression is increased in UC but not CD, suggesting differential regulation among clinical IBD forms.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>41763</offset><text>The nuanced interplay between inflammation and iron status in regulating hepcidin has direct clinical implications. The finding that severe iron deficiency can suppress hepcidin even in active IBD provides a mechanistic rationale for the variable response to oral iron therapy. It suggests that hepcidin measurement could help identify a subset of patients with active inflammation who may still benefit from oral iron if their erythropoietic drive is sufficiently strong to counteract hepcidin-mediated iron blockade.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>42282</offset><text>Experimental models have provided robust evidence about mechanisms regulating hepcidin in intestinal inflammation. Gotardo et al. [2014] demonstrated that TNBS-induced colitis increases hepcidin expression in the colon via the IL-6/STAT3, with local iron accumulation and potential impairment of erythropoiesis.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>42594</offset><text>Likewise, Shanmugam et al. [2012, 2014, 2015] revealed the role of microbiota and cytokines, such as IL-1 and TNF-α, in modulating hepatic hepcidin, highlighting the influence of the gut-liver axis. Other studies emphasized the therapeutic influence of natural compounds. Liu et al. [2019] demonstrated that extracts from Angelica sinensis and Zingiber officinale have a positive modulating effect on hepcidin, reducing inflammation. Conversely, Samba-Mondonga et al. [2019] showed that curcumin, despite being anti-inflammatory, can exacerbate anemia due to its iron-chelating properties.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>43188</offset><text>The study by Bessman et al. [2020] added a new dimension by identifying that intestinal dendritic cells locally produce hepcidin, which contributes to iron sequestration and mucosal repair, indicating mechanisms of nutritional immunity. Therapeutically, Zhao et al. [2020] demonstrated that iron-enriched probiotics, such as Lactobacillus NKU556, can reduce hepcidin levels, enhance intestinal barrier integrity, and increase iron absorption, representing a promising alternative to inorganic iron. Toblli et al. [2015] compared ferrous sulfate and polymaltose complex, concluding that the latter has lower inflammatory potential and may be safer in IBD.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>43843</offset><text>Hepcidin as a biomarker in IBD</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>43874</offset><text>Several studies explored hepcidin as a diagnostic and prognostic biomarker. Aksan et al. [2019] demonstrated that hepcidin levels predict iron absorption capacity in patients with IBD. Similar results were obtained by Loveikyte et al. [2023], who evaluated patients undergoing induction therapy with infliximab or vedolizumab, observing that hepcidin is primarily regulated by iron deficiency, even in the context of active inflammation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>44312</offset><text>Other studies have focused on the association between hepcidin and the type and severity of anemia. Ammar et al. [2022] showed that serum hepcidin effectively distinguishes between iron deficiency anemia and ACD in patients with UC. Similarly, Lalosevic et al. [2020] and Syed et al. [2017] confirmed hepcidin as a reliable marker of iron deficiency, especially when considered in conjunction with other biomarkers such as ferritin, CHr, and sTfR.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>44760</offset><text>In contrast, some studies, such as those by Nagy et al. [2010], questioned the utility of prohepcidin alone as a diagnostic marker, highlighting limitations in its correlation with clinical parameters. Karaskova et al. [2018] and Krawiec et al. [2017], analyzing pediatric populations, observed that hepcidin levels vary between IBD types and that their regulation depends on both inflammation and iron stores.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>45171</offset><text>Heterogeneity in hepcidin assays and sample matrices remains a major obstacle to its clinical application. Studies have used diverse platforms, such as ELISA, RIA, mass spectrometry, and chromatographic methods, on serum, plasma, or urine, and some have quantified prohepcidin rather than the active hepcidin-25. These methodological differences lead to wide variability in absolute values, units, and reference cut-offs, limiting comparability across studies and hindering the definition of diagnostic thresholds.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>45686</offset><text>While urinary hepcidin reflects renal handling and hydration status, serum hepcidin-25 more accurately represents systemic iron regulation; in contrast, prohepcidin shows poor clinical correlation. Thus, methodological heterogeneity must be acknowledged when interpreting results, and harmonization of analytical approaches is essential for clinical translation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>46049</offset><text>It is important to note that hepcidin levels have also been linked to response to oral iron therapy. Rampton et al. [2017] found an inverse relationship between baseline hepcidin levels and response to ferrous sulfate supplementation. The ongoing clinical study by Loveikyte et al. [2024] aims to validate the use of hepcidin as a predictor of response to oral versus intravenous iron.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>46435</offset><text>Hepcidin behaves as an acute-phase protein, with its synthesis upregulated not only by IL-6–mediated inflammation in IBD but also by systemic infections, chronic kidney disease, obesity, and other inflammatory or metabolic comorbidities. Consequently, elevated hepcidin levels may not be specific to intestinal inflammation, as conditions such as infection or obesity can lead to disproportionate increases independent of IBD activity, thereby reducing its diagnostic specificity. These confounding factors underscore the need for a multidimensional assessment that combines hepcidin with other clinical and laboratory parameters. Moreover, although hepcidin-driven mechanisms play a key role in anaemia of inflammation, several additional factors contribute to anaemia in IBD, including chronic gastrointestinal bleeding, malabsorption of vitamin B12 and folate due to ileal or extensive small bowel involvement or resection, and drug-induced cytopenias (e.g., thiopurines). Nutritional deficiencies, particularly during disease flares, further increase the risk of anaemia. Collectively, these aspects highlight the multifactorial nature of anaemia in IBD and the importance of a comprehensive diagnostic approach that extends beyond hepcidin and iron homeostasis.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>47704</offset><text>Effect of IBD treatment on hepcidin regulation</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>47751</offset><text>Clinical studies reinforce the association between inflammation control and hepcidin reduction. Atkinson et al. [2018] observed decreases in hepcidin levels and increased hemoglobin in children with CD treated with anti-TNF-α. Similar results were reported by Shu et al. [2019], identifying the TNF-α/NF-κB pathway as a mediator of hepcidin induction.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>48115</offset><text>Another essential aspect was addressed by Amrousy et al. [2022], who compared the efficacy of ferrous sulfate and lactoferrin. The latter was more effective in improving anemia and reducing IL-6 and hepcidin, suggesting an additional anti-inflammatory effect.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>48375</offset><text>In a longitudinal study, Karaskova et al. [2020] demonstrated that IBD treatment reduces hepcidin levels, which may mediate the recovery of iron metabolism. The data also indicated differences between UC and CD in the dynamics of hepcidin regulation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>48626</offset><text>Emerging therapeutic targets involving hepcidin in IBD</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>48681</offset><text>The only study identified in this group, conducted by Wang et al. [2012], investigated the role of the BMP6/IL-6 pathway in hepcidin induction in mice with colitis. Administration of BMP pathway inhibitors resulted in reduced hepatic hepcidin expression, increased serum iron levels, and attenuation of intestinal inflammation. These data reinforce the potential of hepcidin as a therapeutic target, suggesting that its modulation can simultaneously improve hematologic profile and reduce local inflammation.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">title_2</infon><offset>49190</offset><text>Limitations of the systematic review</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>49227</offset><text>Despite the relevance of the findings gathered in this review, some limitations must be acknowledged. The main one concerns the heterogeneity of the included studies, both regarding the evaluated populations (adults vs. pediatric, varied clinical forms of IBD, and different disease stages) and the methods used to measure hepcidin (immunoassays, liquid chromatography, urinary measurement, among others), as well as the analyzed outcomes (anemia, inflammatory activity, therapeutic response, and iron parameters). This variability hinders direct comparison between studies and limits the possibility of broad generalizations.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>49854</offset><text>Given the marked heterogeneity among the included studies in terms of design, study population, and outcome assessment, a quantitative synthesis was not performed. The studies differed substantially in patient characteristics (adults vs. children, CD vs. UC, and varying disease activity levels), hepcidin quantification methods (serum or urine, ELISA or mass spectrometry), and analytical units. These methodological discrepancies precluded data pooling; thus, a qualitative synthesis was deemed the most appropriate strategy to ensure accurate and transparent interpretation of findings. Collectively, the evidence positions hepcidin as a promising correlative and predictive biomarker rather than a definitive diagnostic tool.</text></passage><passage><infon key="section_type">DISCUSS</infon><infon key="type">paragraph</infon><offset>50584</offset><text>Future research should prioritize methodological harmonization and the establishment of consensus reference standards to clarify its clinical applicability. Nevertheless, the analyzed data allow us to conclude that hepcidin plays a central role at the intersection between inflammation and iron metabolism in IBD. Its levels are modulated by inflammatory cytokines, especially IL-6 and TNF-α, and directly influence iron bioavailability, contributing to the development of anemia of chronic disease. Moreover, hepcidin has proven to be a promising biomarker for assessing iron status and response to oral or intravenous iron therapy, in addition to being modulated by anti-inflammatory treatments such as biologic agents and lactoferrin. Experimental studies also reinforce its potential as a therapeutic target.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>51401</offset><text>Conclusions</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>51413</offset><text>Hepcidin plays a central role in iron homeostasis and in the pathophysiology of anemia associated with IBD. Robust evidence indicates that its levels are modulated by inflammatory mediators, iron stores, and erythropoietic activity, correlating with disease severity and response to iron therapy. In this context, hepcidin emerges as a promising biomarker, with the potential to distinguish iron deficiency anemia from anemia of chronic disease, as well as to guide decisions regarding the most appropriate route of iron supplementation. However, despite these encouraging findings, methodological heterogeneity among studies—regarding analytical techniques and patient populations—limits broader clinical application. Therefore, further studies with standardized methodologies are needed to validate the clinical utility of hepcidin and to explore its potential as a therapeutic target in IBD.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>52312</offset><text>Supplementary</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>52326</offset><text>Reporting Checklist: The authors have completed the PRISMA reporting checklist. Available at https://tgh.amegroups.com/article/view/10.21037/tgh-25-99/rc</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>52480</offset><text>Funding: This work was supported by  ( for L.F.P.), by  ( for S.S.N.S. and  for I.M.P. L.M.G.), by  ( for R.F.L.), and by  ( for L.M.G.).</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">footnote</infon><offset>52618</offset><text>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tgh.amegroups.com/article/view/10.21037/tgh-25-99/coif). The authors have no conflicts of interest to declare.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>52835</offset><text>Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>53043</offset><text>References</text></passage><passage><infon key="fpage">1606</infon><infon key="lpage">19</infon><infon key="name_0">surname:Ordás;given-names:I</infon><infon key="name_1">surname:Eckmann;given-names:L</infon><infon key="name_2">surname:Talamini;given-names:M</infon><infon key="pub-id_doi">10.1016/S0140-6736(12)60150-0</infon><infon key="pub-id_pmid">22914296</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">380</infon><infon key="year">2012</infon><offset>53054</offset><text>Ulcerative colitis.</text></passage><passage><infon key="fpage">2769</infon><infon key="lpage">78</infon><infon key="name_0">surname:Ng;given-names:SC</infon><infon key="name_1">surname:Shi;given-names:HY</infon><infon key="name_2">surname:Hamidi;given-names:N</infon><infon key="pub-id_doi">10.1016/S0140-6736(17)32448-0</infon><infon key="pub-id_pmid">29050646</infon><infon key="section_type">REF</infon><infon key="source">Lancet</infon><infon key="type">ref</infon><infon key="volume">390</infon><infon key="year">2017</infon><offset>53074</offset><text>Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies.</text></passage><passage><infon key="fpage">127</infon><infon key="lpage">48</infon><infon key="name_0">surname:Liu;given-names:TC</infon><infon key="name_1">surname:Stappenbeck;given-names:TS</infon><infon key="pub-id_doi">10.1146/annurev-pathol-012615-044152</infon><infon key="pub-id_pmid">26907531</infon><infon key="section_type">REF</infon><infon key="source">Annu Rev Pathol</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2016</infon><offset>53209</offset><text>Genetics and Pathogenesis of Inflammatory Bowel Disease.</text></passage><passage><infon key="fpage">1011</infon><infon key="lpage">23</infon><infon key="name_0">surname:Weiss;given-names:G</infon><infon key="name_1">surname:Goodnough;given-names:LT</infon><infon key="pub-id_doi">10.1056/NEJMra041809</infon><infon key="pub-id_pmid">15758012</infon><infon key="section_type">REF</infon><infon key="source">N Engl J Med</infon><infon key="type">ref</infon><infon key="volume">352</infon><infon key="year">2005</infon><offset>53266</offset><text>Anemia of chronic disease.</text></passage><passage><infon key="fpage">899</infon><infon key="lpage">910</infon><infon key="name_0">surname:Aschemeyer;given-names:S</infon><infon key="name_1">surname:Qiao;given-names:B</infon><infon key="name_2">surname:Stefanova;given-names:D</infon><infon key="pub-id_doi">10.1182/blood-2017-05-786590</infon><infon key="pub-id_pmid">29237594</infon><infon key="section_type">REF</infon><infon key="source">Blood</infon><infon key="type">ref</infon><infon key="volume">131</infon><infon key="year">2018</infon><offset>53293</offset><text>Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.</text></passage><passage><infon key="fpage">2090</infon><infon key="lpage">3</infon><infon key="name_0">surname:Nemeth;given-names:E</infon><infon key="name_1">surname:Tuttle;given-names:MS</infon><infon key="name_2">surname:Powelson;given-names:J</infon><infon key="pub-id_doi">10.1126/science.1104742</infon><infon key="pub-id_pmid">15514116</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">306</infon><infon key="year">2004</infon><offset>53413</offset><text>Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization.</text></passage><passage><infon key="fpage">1434</infon><infon key="lpage">43</infon><infon key="name_0">surname:Ganz;given-names:T</infon><infon key="name_1">surname:Nemeth;given-names:E</infon><infon key="pub-id_doi">10.1016/j.bbamcr.2012.01.014</infon><infon key="pub-id_pmid">22306005</infon><infon key="section_type">REF</infon><infon key="source">Biochim Biophys Acta</infon><infon key="type">ref</infon><infon key="volume">1823</infon><infon key="year">2012</infon><offset>53513</offset><text>Hepcidin and iron homeostasis.</text></passage><passage><infon key="fpage">1691</infon><infon key="lpage">702</infon><infon key="name_0">surname:Nairz;given-names:M</infon><infon key="name_1">surname:Schroll;given-names:A</infon><infon key="name_2">surname:Sonnweber;given-names:T</infon><infon key="pub-id_doi">10.1111/j.1462-5822.2010.01529.x</infon><infon key="pub-id_pmid">20964797</infon><infon key="section_type">REF</infon><infon key="source">Cell Microbiol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2010</infon><offset>53544</offset><text>The struggle for iron - a metal at the host-pathogen interface.</text></passage><passage><infon key="fpage">46</infon><infon key="issue">1</infon><infon key="lpage">56</infon><infon key="name_0">surname:Kautz;given-names:L</infon><infon key="name_1">surname:Nemeth;given-names:E</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Gastroenterol Hepatol.</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2022</infon><offset>53608</offset><text>Hepcidin and iron disorders: new biology and clinical applications.</text></passage><passage><infon key="fpage">383</infon><infon key="lpage">4</infon><infon key="name_0">surname:Bernardo;given-names:WM</infon><infon key="pub-id_doi">10.1590/S1677-5538.IBJU.2017.03.02</infon><infon key="pub-id_pmid">28520335</infon><infon key="section_type">REF</infon><infon key="source">Int Braz J Urol</infon><infon key="type">ref</infon><infon key="volume">43</infon><infon key="year">2017</infon><offset>53676</offset><text>PRISMA statement and PROSPERO.</text></passage><passage><infon key="fpage">160</infon><infon key="name_0">surname:Valizadeh;given-names:A</infon><infon key="name_1">surname:Moassefi;given-names:M</infon><infon key="name_2">surname:Nakhostin-Ansari;given-names:A</infon><infon key="pub-id_doi">10.1186/s12874-022-01631-8</infon><infon key="pub-id_pmid">35655155</infon><infon key="section_type">REF</infon><infon key="source">BMC Med Res Methodol</infon><infon key="type">ref</infon><infon key="volume">22</infon><infon key="year">2022</infon><offset>53707</offset><text>Abstract screening using the automated tool Rayyan: results of effectiveness in three diagnostic test accuracy systematic reviews.</text></passage><passage><infon key="fpage">425</infon><infon key="lpage">9</infon><infon key="name_0">surname:Arnold;given-names:J</infon><infon key="name_1">surname:Sangwaiya;given-names:A</infon><infon key="name_2">surname:Bhatkal;given-names:B</infon><infon key="pub-id_doi">10.1097/MEG.0b013e32830e2885</infon><infon key="pub-id_pmid">19262400</infon><infon key="section_type">REF</infon><infon key="source">Eur J Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2009</infon><offset>53838</offset><text>Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis.</text></passage><passage><infon key="fpage">e286</infon><infon key="lpage">91</infon><infon key="name_0">surname:Basseri;given-names:RJ</infon><infon key="name_1">surname:Nemeth;given-names:E</infon><infon key="name_2">surname:Vassilaki;given-names:ME</infon><infon key="pub-id_doi">10.1016/j.crohns.2012.10.013</infon><infon key="pub-id_pmid">23219355</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2013</infon><offset>53928</offset><text>Hepcidin is a key mediator of anemia of inflammation in Crohn's disease.</text></passage><passage><infon key="fpage">2166</infon><infon key="lpage">72</infon><infon key="name_0">surname:Bergamaschi;given-names:G</infon><infon key="name_1">surname:Di Sabatino;given-names:A</infon><infon key="name_2">surname:Albertini;given-names:R</infon><infon key="pub-id_doi">10.1097/MIB.0b013e31829a6e43</infon><infon key="pub-id_pmid">23867871</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">19</infon><infon key="year">2013</infon><offset>54001</offset><text>Serum hepcidin in inflammatory bowel diseases: biological and clinical significance.</text></passage><passage><infon key="fpage">1101</infon><infon key="lpage">6</infon><infon key="name_0">surname:Semrin;given-names:G</infon><infon key="name_1">surname:Fishman;given-names:DS</infon><infon key="name_2">surname:Bousvaros;given-names:A</infon><infon key="pub-id_doi">10.1097/01.mib.0000235097.86360.04</infon><infon key="pub-id_pmid">17119383</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2006</infon><offset>54086</offset><text>Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation.</text></passage><passage><infon key="fpage">1392</infon><infon key="lpage">7</infon><infon key="name_0">surname:Mecklenburg;given-names:I</infon><infon key="name_1">surname:Reznik;given-names:D</infon><infon key="name_2">surname:Fasler-Kan;given-names:E</infon><infon key="pub-id_doi">10.1016/j.crohns.2014.04.008</infon><infon key="pub-id_pmid">24825446</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">8</infon><infon key="year">2014</infon><offset>54203</offset><text>Serum hepcidin concentrations correlate with ferritin in patients with inflammatory bowel disease.</text></passage><passage><infon key="fpage">28</infon><infon key="lpage">34</infon><infon key="name_0">surname:Ammar;given-names:Samar Reda</infon><infon key="name_1">surname:Ghazy;given-names:Medhat A.</infon><infon key="name_2">surname:Mabrouk;given-names:Maaly M</infon><infon key="name_3">surname:Gawaly;given-names:Amr M.</infon><infon key="section_type">REF</infon><infon key="source">Journal of Applied Hematology</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>54302</offset><text>Role of serum hepcidin and reticulocyte hemoglobin concentration in evaluation of anemia in ulcerative colitis patients.</text></passage><passage><infon key="fpage">706</infon><infon key="lpage">15</infon><infon key="name_0">surname:Rampton;given-names:DS</infon><infon key="name_1">surname:Goodhand;given-names:JR</infon><infon key="name_2">surname:Joshi;given-names:NM</infon><infon key="pub-id_doi">10.1093/ecco-jcc/jjw208</infon><infon key="pub-id_pmid">27932449</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2017</infon><offset>54423</offset><text>Oral Iron Treatment Response and Predictors in Anaemic Adolescents and Adults with IBD: A Prospective Controlled Open-Label Trial.</text></passage><passage><infon key="fpage">90</infon><infon key="lpage">4</infon><infon key="name_0">surname:Atkinson;given-names:MA</infon><infon key="name_1">surname:Leonard;given-names:MB</infon><infon key="name_2">surname:Herskovitz;given-names:R</infon><infon key="pub-id_doi">10.1097/MPG.0000000000001650</infon><infon key="pub-id_pmid">28604512</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr Gastroenterol Nutr</infon><infon key="type">ref</infon><infon key="volume">66</infon><infon key="year">2018</infon><offset>54554</offset><text>Changes in Hepcidin and Hemoglobin After Anti-TNF-alpha Therapy in Children and Adolescents With Crohn Disease.</text></passage><passage><infon key="fpage">1272</infon><infon key="lpage">84</infon><infon key="name_0">surname:Loveikyte;given-names:R</infon><infon key="name_1">surname:Bourgonje;given-names:AR</infon><infon key="name_2">surname:van der Reijden;given-names:JJ</infon><infon key="pub-id_doi">10.1093/ibd/izad010</infon><infon key="pub-id_pmid">36748574</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">29</infon><infon key="year">2023</infon><offset>54666</offset><text>Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab.</text></passage><passage><infon key="fpage">1362</infon><infon key="lpage">7</infon><infon key="name_0">surname:Karaskova;given-names:E</infon><infon key="name_1">surname:Volejnikova;given-names:J</infon><infon key="name_2">surname:Holub;given-names:D</infon><infon key="pub-id_doi">10.1111/jpc.14093</infon><infon key="pub-id_pmid">29923651</infon><infon key="section_type">REF</infon><infon key="source">J Paediatr Child Health</infon><infon key="type">ref</infon><infon key="volume">54</infon><infon key="year">2018</infon><offset>54796</offset><text>Hepcidin in newly diagnosed inflammatory bowel disease in children.</text></passage><passage><infon key="fpage">112</infon><infon key="lpage">9</infon><infon key="name_0">surname:Wang;given-names:L</infon><infon key="name_1">surname:Trebicka;given-names:E</infon><infon key="name_2">surname:Fu;given-names:Y</infon><infon key="pub-id_doi">10.1002/ibd.21675</infon><infon key="pub-id_pmid">21351217</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2012</infon><offset>54864</offset><text>The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease.</text></passage><passage><infon key="fpage">4345</infon><infon key="lpage">52</infon><infon key="name_0">surname:Gotardo;given-names:ÉM</infon><infon key="name_1">surname:Ribeiro Gde;given-names:A</infon><infon key="name_2">surname:Clemente;given-names:TR</infon><infon key="pub-id_doi">10.3748/wjg.v20.i15.4345</infon><infon key="pub-id_pmid">24764672</infon><infon key="section_type">REF</infon><infon key="source">World J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2014</infon><offset>54964</offset><text>Hepcidin expression in colon during trinitrobenzene sulfonic acid-induced colitis in rats.</text></passage><passage><infon key="fpage">186</infon><infon key="lpage">9</infon><infon key="name_0">surname:Bessman;given-names:NJ</infon><infon key="name_1">surname:Mathieu;given-names:JRR</infon><infon key="name_2">surname:Renassia;given-names:C</infon><infon key="pub-id_doi">10.1126/science.aau6481</infon><infon key="pub-id_pmid">32273468</infon><infon key="section_type">REF</infon><infon key="source">Science</infon><infon key="type">ref</infon><infon key="volume">368</infon><infon key="year">2020</infon><offset>55055</offset><text>Dendritic cell-derived hepcidin sequesters iron from the microbiota to promote mucosal healing.</text></passage><passage><infon key="fpage">12028</infon><infon key="lpage">38</infon><infon key="name_0">surname:Zhao;given-names:N</infon><infon key="name_1">surname:Liu;given-names:JM</infon><infon key="name_2">surname:Yang;given-names:FE</infon><infon key="pub-id_doi">10.1021/acs.jafc.0c05260</infon><infon key="pub-id_pmid">33052690</infon><infon key="section_type">REF</infon><infon key="source">J Agric Food Chem</infon><infon key="type">ref</infon><infon key="volume">68</infon><infon key="year">2020</infon><offset>55151</offset><text>A Novel Mediation Strategy of DSS-Induced Colitis in Mice Based on an Iron-Enriched Probiotic and In Vivo Bioluminescence Tracing.</text></passage><passage><infon key="fpage">2585</infon><infon key="lpage">97</infon><infon key="name_0">surname:Toblli;given-names:JE</infon><infon key="name_1">surname:Cao;given-names:G</infon><infon key="name_2">surname:Angerosa;given-names:M</infon><infon key="section_type">REF</infon><infon key="source">Drug Des Devel Ther</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2015</infon><offset>55282</offset><text>Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats.</text></passage><passage><infon key="fpage">566</infon><infon key="lpage">74</infon><infon key="name_0">surname:Martinelli;given-names:M</infon><infon key="name_1">surname:Strisciuglio;given-names:C</infon><infon key="name_2">surname:Alessandrella;given-names:A</infon><infon key="pub-id_doi">10.1093/ecco-jcc/jjv242</infon><infon key="pub-id_pmid">26733407</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2016</infon><offset>55448</offset><text>Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease.</text></passage><passage><infon key="fpage">1287</infon><infon key="lpage">91</infon><infon key="name_0">surname:Moran-Lev;given-names:H</infon><infon key="name_1">surname:Galai;given-names:T</infon><infon key="name_2">surname:Yerushalmy-Feler;given-names:A</infon><infon key="pub-id_doi">10.1093/ecco-jcc/jjz056</infon><infon key="pub-id_pmid">30840757</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2019</infon><offset>55525</offset><text>Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study.</text></passage><passage><infon key="elocation-id">e00450</infon><infon key="name_0">surname:Stallhofer;given-names:J</infon><infon key="name_1">surname:Veith;given-names:L</infon><infon key="name_2">surname:Diegelmann;given-names:J</infon><infon key="pub-id_doi">10.14309/ctg.0000000000000450</infon><infon key="pub-id_pmid">35029158</infon><infon key="section_type">REF</infon><infon key="source">Clin Transl Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>55667</offset><text>Iron Deficiency in Inflammatory Bowel Disease Is Associated With Low Levels of Vitamin D Modulating Serum Hepcidin and Intestinal Ceruloplasmin Expression.</text></passage><passage><infon key="fpage">567</infon><infon key="lpage">83</infon><infon key="name_0">surname:Li;given-names:X</infon><infon key="name_1">surname:LeBlanc;given-names:J</infon><infon key="name_2">surname:Elashoff;given-names:D</infon><infon key="pub-id_doi">10.1016/j.jcmgh.2016.05.003</infon><infon key="pub-id_pmid">28174738</infon><infon key="section_type">REF</infon><infon key="source">Cell Mol Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">2</infon><infon key="year">2016</infon><offset>55823</offset><text>Microgeographic Proteomic Networks of the Human Colonic Mucosa and Their Association With Inflammatory Bowel Disease.</text></passage><passage><infon key="fpage">524</infon><infon key="lpage">31</infon><infon key="name_0">surname:Burpee;given-names:T</infon><infon key="name_1">surname:Mitchell;given-names:P</infon><infon key="name_2">surname:Fishman;given-names:D</infon><infon key="pub-id_doi">10.1002/ibd.21367</infon><infon key="pub-id_pmid">20564534</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2011</infon><offset>55941</offset><text>Intestinal ferroportin expression in pediatric Crohn's disease.</text></passage><passage><infon key="fpage">262</infon><infon key="lpage">8</infon><infon key="name_0">surname:Oustamanolakis;given-names:P</infon><infon key="name_1">surname:Koutroubakis;given-names:IE</infon><infon key="name_2">surname:Messaritakis;given-names:I</infon><infon key="pub-id_doi">10.1097/MEG.0b013e328343b885</infon><infon key="pub-id_pmid">21285884</infon><infon key="section_type">REF</infon><infon key="source">Eur J Gastroenterol Hepatol</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2011</infon><offset>56005</offset><text>Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease.</text></passage><passage><infon key="fpage">762</infon><infon key="lpage">6</infon><infon key="name_0">surname:El Amrousy;given-names:D</infon><infon key="name_1">surname:El-Afify;given-names:D</infon><infon key="name_2">surname:Elsawy;given-names:A</infon><infon key="pub-id_doi">10.1038/s41390-022-02136-2</infon><infon key="pub-id_pmid">35681097</infon><infon key="section_type">REF</infon><infon key="source">Pediatr Res</infon><infon key="type">ref</infon><infon key="volume">92</infon><infon key="year">2022</infon><offset>56082</offset><text>Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial.</text></passage><passage><infon key="fpage">649</infon><infon key="lpage">53</infon><infon key="name_0">surname:Nagy;given-names:J</infon><infon key="name_1">surname:Lakner;given-names:L</infon><infon key="name_2">surname:Poór;given-names:VS</infon><infon key="pub-id_doi">10.1016/j.crohns.2010.07.010</infon><infon key="pub-id_pmid">21122575</infon><infon key="section_type">REF</infon><infon key="source">J Crohns Colitis</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2010</infon><offset>56184</offset><text>Serum prohepcidin levels in chronic inflammatory bowel diseases.</text></passage><passage><infon key="elocation-id">4038619</infon><infon key="name_0">surname:Shu;given-names:W</infon><infon key="name_1">surname:Pang;given-names:Z</infon><infon key="name_2">surname:Xu;given-names:C</infon><infon key="pub-id_doi">10.1155/2019/4038619</infon><infon key="pub-id_pmid">31814801</infon><infon key="section_type">REF</infon><infon key="source">Mediators Inflamm</infon><infon key="type">ref</infon><infon key="volume">2019</infon><infon key="year">2019</infon><offset>56249</offset><text>Anti-TNF-α Monoclonal Antibody Therapy Improves Anemia through Downregulating Hepatocyte Hepcidin Expression in Inflammatory Bowel Disease.</text></passage><passage><infon key="fpage">30637</infon><infon key="lpage">47</infon><infon key="name_0">surname:Shanmugam;given-names:NK</infon><infon key="name_1">surname:Chen;given-names:K</infon><infon key="name_2">surname:Cherayil;given-names:BJ</infon><infon key="pub-id_doi">10.1074/jbc.M115.689190</infon><infon key="pub-id_pmid">26515063</infon><infon key="section_type">REF</infon><infon key="source">J Biol Chem</infon><infon key="type">ref</infon><infon key="volume">290</infon><infon key="year">2015</infon><offset>56393</offset><text>Commensal Bacteria-induced Interleukin 1β (IL-1β) Secreted by Macrophages Up-regulates Hepcidin Expression in Hepatocytes by Activating the Bone Morphogenetic Protein Signaling Pathway.</text></passage><passage><infon key="elocation-id">e38136</infon><infon key="name_0">surname:Shanmugam;given-names:NK</infon><infon key="name_1">surname:Ellenbogen;given-names:S</infon><infon key="name_2">surname:Trebicka;given-names:E</infon><infon key="pub-id_doi">10.1371/journal.pone.0038136</infon><infon key="pub-id_pmid">22675442</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2012</infon><offset>56585</offset><text>Tumor necrosis factor α inhibits expression of the iron regulating hormone hepcidin in murine models of innate colitis.</text></passage><passage><infon key="fpage">1398</infon><infon key="lpage">407</infon><infon key="name_0">surname:Shanmugam;given-names:NK</infon><infon key="name_1">surname:Trebicka;given-names:E</infon><infon key="name_2">surname:Fu;given-names:LL</infon><infon key="pub-id_doi">10.4049/jimmunol.1400278</infon><infon key="pub-id_pmid">24973448</infon><infon key="section_type">REF</infon><infon key="source">J Immunol</infon><infon key="type">ref</infon><infon key="volume">193</infon><infon key="year">2014</infon><offset>56709</offset><text>Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota.</text></passage><passage><infon key="fpage">3816</infon><infon key="name_0">surname:Liu;given-names:J</infon><infon key="name_1">surname:Yu;given-names:L</infon><infon key="name_2">surname:Mo;given-names:N</infon><infon key="pub-id_doi">10.3390/ijms20153816</infon><infon key="pub-id_pmid">31387229</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2019</infon><offset>56861</offset><text>Supercritical Fluid Extract of Angelica sinensis and Zingiber officinale Roscoe Ameliorates TNBS-Induced Colitis in Rats.</text></passage><passage><infon key="elocation-id">e0208677</infon><infon key="name_0">surname:Samba-Mondonga;given-names:M</infon><infon key="name_1">surname:Constante;given-names:M</infon><infon key="name_2">surname:Fragoso;given-names:G</infon><infon key="pub-id_doi">10.1371/journal.pone.0208677</infon><infon key="pub-id_pmid">31026259</infon><infon key="section_type">REF</infon><infon key="source">PLoS One</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2019</infon><offset>56983</offset><text>Curcumin induces mild anemia in a DSS-induced colitis mouse model maintained on an iron-sufficient diet.</text></passage><passage><infon key="name_0">surname:Aksan;given-names:A</infon><infon key="name_1">surname:Wohlrath;given-names:M</infon><infon key="name_2">surname:Iqbal;given-names:TH</infon><infon key="section_type">REF</infon><infon key="source">Clin Lab</infon><infon key="type">ref</infon><infon key="year">2019</infon><offset>57088</offset><text>Serum Hepcidin Levels Predict Intestinal Iron Absorption in Patients with Inflammatory Bowel Disease.</text></passage><passage><infon key="elocation-id">8523205</infon><infon key="name_0">surname:Stojkovic Lalosevic;given-names:M</infon><infon key="name_1">surname:Toncev;given-names:L</infon><infon key="name_2">surname:Stankovic;given-names:S</infon><infon key="pub-id_doi">10.1155/2020/8523205</infon><infon key="pub-id_pmid">33354248</infon><infon key="section_type">REF</infon><infon key="source">Dis Markers</infon><infon key="type">ref</infon><infon key="volume">2020</infon><infon key="year">2020</infon><offset>57190</offset><text>Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease.</text></passage><passage><infon key="fpage">713</infon><infon key="lpage">20</infon><infon key="name_0">surname:Syed;given-names:S</infon><infon key="name_1">surname:Kugathasan;given-names:S</infon><infon key="name_2">surname:Kumar;given-names:A</infon><infon key="pub-id_doi">10.1097/MPG.0000000000001335</infon><infon key="pub-id_pmid">27429427</infon><infon key="section_type">REF</infon><infon key="source">J Pediatr Gastroenterol Nutr</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="year">2017</infon><offset>57307</offset><text>Use of Reticulocyte Hemoglobin Content in the Assessment of Iron Deficiency in Children With Inflammatory Bowel Disease.</text></passage><passage><infon key="fpage">2165</infon><infon key="lpage">71</infon><infon key="name_0">surname:Krawiec;given-names:P</infon><infon key="name_1">surname:Mroczkowska-Juchkiewicz;given-names:A</infon><infon key="name_2">surname:Pac-Kożuchowska;given-names:E.</infon><infon key="pub-id_doi">10.1097/MIB.0000000000001245</infon><infon key="pub-id_pmid">28945637</infon><infon key="section_type">REF</infon><infon key="source">Inflamm Bowel Dis</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2017</infon><offset>57428</offset><text>Serum Hepcidin in Children with Inflammatory Bowel Disease.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>57488</offset><text>Peer Review File</text></passage><passage><infon key="section_type">REF</infon><infon key="type">paragraph</infon><offset>57505</offset><text>Available at https://tgh.amegroups.com/article/view/10.21037/tgh-25-99/prf</text></passage></document>
</collection>